267 related articles for article (PubMed ID: 22503783)
1. Parallels between behavioral and neurochemical variability in the rat vacuous chewing movement model of tardive dyskinesia.
Bachus SE; Yang E; McCloskey SS; Minton JN
Behav Brain Res; 2012 Jun; 231(2):323-36. PubMed ID: 22503783
[TBL] [Abstract][Full Text] [Related]
2. Protective effect of Curcumin, the active principle of turmeric (Curcuma longa) in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes in rat brain.
Bishnoi M; Chopra K; Kulkarni SK
Pharmacol Biochem Behav; 2008 Feb; 88(4):511-22. PubMed ID: 18022680
[TBL] [Abstract][Full Text] [Related]
3. Differential striatal levels of TNF-alpha, NFkappaB p65 subunit and dopamine with chronic typical and atypical neuroleptic treatment: role in orofacial dyskinesia.
Bishnoi M; Chopra K; Kulkarni SK
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1473-8. PubMed ID: 18554768
[TBL] [Abstract][Full Text] [Related]
4. Electron spin resonance spectroscopy reveals alpha-phenyl-N-tert-butylnitrone spin-traps free radicals in rat striatum and prevents haloperidol-induced vacuous chewing movements in the rat model of human tardive dyskinesia.
Rogoza RM; Fairfax DF; Henry P; N-Marandi S; Khan RF; Gupta SK; Mishra RK
Synapse; 2004 Dec; 54(3):156-63. PubMed ID: 15452862
[TBL] [Abstract][Full Text] [Related]
5. Effect of 5-HT1A and 5-HT2A/2C receptor modulation on neuroleptic-induced vacuous chewing movements.
Naidu PS; Kulkarni SK
Eur J Pharmacol; 2001 Sep; 428(1):81-6. PubMed ID: 11779040
[TBL] [Abstract][Full Text] [Related]
6. Involvement of adenosinergic receptor system in an animal model of tardive dyskinesia and associated behavioural, biochemical and neurochemical changes.
Bishnoi M; Chopra K; Kulkarni SK
Eur J Pharmacol; 2006 Dec; 552(1-3):55-66. PubMed ID: 17064683
[TBL] [Abstract][Full Text] [Related]
7. Neurochemical changes in the entopeduncular nucleus and increased oral behavior in rats treated subchronically with clozapine or haloperidol.
Yu J; Källström L; Wiesel FA; Johnson AE
Synapse; 1999 Dec; 34(3):192-207. PubMed ID: 10523757
[TBL] [Abstract][Full Text] [Related]
8. Possible anti-oxidant and neuroprotective mechanisms of zolpidem in attenuating typical anti-psychotic-induced orofacial dyskinesia: a biochemical and neurochemical study.
Bishnoi M; Chopra K; Kulkarni SK
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1130-8. PubMed ID: 17513028
[TBL] [Abstract][Full Text] [Related]
9. Valeriana officinalis does not alter the orofacial dyskinesia induced by haloperidol in rats: role of dopamine transporter.
Fachinetto R; Villarinho JG; Wagner C; Pereira RP; Avila DS; Burger ME; Calixto JB; Rocha JB; Ferreira J
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1478-86. PubMed ID: 17669571
[TBL] [Abstract][Full Text] [Related]
10. Beneficial effects of lycopene against haloperidol induced orofacial dyskinesia in rats: Possible neurotransmitters and neuroinflammation modulation.
Datta S; Jamwal S; Deshmukh R; Kumar P
Eur J Pharmacol; 2016 Jan; 771():229-35. PubMed ID: 26712377
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological and neurochemical differences between acute and tardive vacuous chewing movements induced by haloperidol.
Egan MF; Hurd Y; Ferguson J; Bachus SE; Hamid EH; Hyde TM
Psychopharmacology (Berl); 1996 Oct; 127(4):337-45. PubMed ID: 8923569
[TBL] [Abstract][Full Text] [Related]
12. Oral Dyskinesias and striatal lesions in rats after long-term co-treatment with haloperidol and 3-nitropropionic acid.
Andreassen OA; Ferrante RJ; Beal MF; Jørgensen HA
Neuroscience; 1998 Dec; 87(3):639-48. PubMed ID: 9758230
[TBL] [Abstract][Full Text] [Related]
13. Modulatory effect of neurosteroids in haloperidol-induced vacuous chewing movements and related behaviors.
Bishnoi M; Chopra K; Kulkarni SK
Psychopharmacology (Berl); 2008 Feb; 196(2):243-54. PubMed ID: 17955214
[TBL] [Abstract][Full Text] [Related]
14. Differential effects of antipsychotics on haloperidol-induced vacuous chewing movements and subcortical gene expression in the rat.
McCullumsmith RE; Stincic TL; Agrawal SM; Meador-Woodruff JH
Eur J Pharmacol; 2003 Sep; 477(2):101-12. PubMed ID: 14519413
[TBL] [Abstract][Full Text] [Related]
15. The relationship between dopamine D2 receptor occupancy and the vacuous chewing movement syndrome in rats.
Turrone P; Remington G; Kapur S; Nobrega JN
Psychopharmacology (Berl); 2003 Jan; 165(2):166-71. PubMed ID: 12417967
[TBL] [Abstract][Full Text] [Related]
16. Co-administration of nitric oxide (NO) donors prevents haloperidol-induced orofacial dyskinesia, oxidative damage and change in striatal dopamine levels.
Bishnoi M; Chopra K; Kulkarni SK
Pharmacol Biochem Behav; 2009 Jan; 91(3):423-9. PubMed ID: 18789960
[TBL] [Abstract][Full Text] [Related]
17. Autoradiographic mapping of mu opioid receptor changes in rat brain after long-term haloperidol treatment: relationship to the development of vacuous chewing movements.
Sasaki T; Kennedy JL; Nobrega JN
Psychopharmacology (Berl); 1996 Nov; 128(1):97-104. PubMed ID: 8944412
[TBL] [Abstract][Full Text] [Related]
18. Protective effect of rutin, a polyphenolic flavonoid against haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes.
Bishnoi M; Chopra K; Kulkarni SK
Fundam Clin Pharmacol; 2007 Oct; 21(5):521-9. PubMed ID: 17868205
[TBL] [Abstract][Full Text] [Related]
19. Neurochemical changes associated with chronic administration of typical antipsychotics and its relationship with tardive dyskinesia.
Bishnoi M; Chopra K; Kulkarni SK
Methods Find Exp Clin Pharmacol; 2007 Apr; 29(3):211-6. PubMed ID: 17520104
[TBL] [Abstract][Full Text] [Related]
20. Alterations in mRNA levels of D2 receptors and neuropeptides in striatonigral and striatopallidal neurons of rats with neuroleptic-induced dyskinesias.
Egan MF; Hurd Y; Hyde TM; Weinberger DR; Wyatt RJ; Kleinman JE
Synapse; 1994 Nov; 18(3):178-89. PubMed ID: 7531873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
